As these second-generation inhibitors are also in Phase I development for adult cancers [NCT06672523; NCT063690354; NCT06137144; NCT06130553; NCT06589596], including adult sarcoma [NCT05732831], a clinical trial with one of these inhibitors in ES patients with MTAP deletion could also be considered after further preclinical in vitro and in vivo assessment. This evidence concerns the gene MTAP and cancer.